Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database

Alorfi, Nasser M.; Alshehri, Fahad S.; Haseeb, Abdul

doi:10.3389/fpubh.2023.1144325

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, investigating susceptibility to tecovirimat in patients as part of clinical trials will also be extremely important, and several protocols are being implemented in different countries to address this issue. 21 , 37 , 38 The number of clinical isolates is also a limitation of our study. However, the isolation and manipulation of MPXV, a BSL-3 pathogen, requires strict biosafety protocols that restrict the workload.…”

Section: Discussionmentioning

confidence: 99%

In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat

Nunes

Higa

Oliveira

et al. 2023

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

BACKGROUND In 2022, an outbreak of mpox that started in European countries spread worldwide through human-to-human transmission. Cases have been mostly mild, but severe clinical presentations have been reported. In these cases, tecovirimat has been the drug of choice to treat patients with aggravated disease. OBJECTIVES Here we investigated the tecovirimat susceptibility of 18 clinical isolates of monkeypox virus (MPXV) obtained from different regions of Brazil. METHODS Different concentrations of tecovirimat were added to cell monolayers infected with each MPXV isolate. After 72 hours, cells were fixed and stained for plaque visualization, counting, and measurement. The ortholog of F13L gene from each MPXV isolate was polymerase chain reaction (PCR)-amplified, sequenced, and the predicted protein sequences were analyzed. FINDINGS The eighteen MPXV isolates generated plaques of different sizes. Although all isolates were highly sensitive to the drug, two showed different response curves and IC 50 values. However, the target protein of tecovirimat, F13 (VP37), was 100% conserved in all MPXV isolates and therefore does not explain the difference in sensitivity. MAIN CONCLUSIONS Our results support screening different MPXV isolates for tecovirimat susceptibility as an important tool to better use of the restricted number of tecovirimat doses available in low-income countries to treat patients with mpox.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat

Nunes

Higa

Oliveira

et al. 2023

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…A limited number of clinical trials have been registered on ClinicalTrials.gov focusing on antiviral drugs (tecovirimat) and vaccines for testing efficacy and safety in hMPXV infection since the first case of mpox was reported [52]. Currently, a randomised trial is underway to study the effectiveness of tecovirimat in the hMPOX outbreak [53].…”

Section: Clinical Trials Of Tecovirimatementioning

confidence: 99%

Monkeypox: From Emerging Trends to Therapeutic Concerns

Piparva,

Fichadiya,

Joshi

et al. 2024

Cureus

View full text Add to dashboard Cite

Monkeypox is a zoonotic viral disease. Monkeypox was first reported in humans about 54 years ago. Prior to the global outbreak, monkeypox was endemic to the rainforests of central and western African countries. In the last three years, increasing numbers of human monkeypox have been reported from various countries. Responding to the severity, monkeypox was declared a Public Health Emergency of International Concern by the World Health Organization. In the absence of approved drugs or clinical studies, repurposed drugs and therapeutic medical countermeasures effective against other orthopoxviruses have been utilized to treat severe human monkeypox cases. Currently, clinical trials are underway exploring the potential therapeutic effectiveness of tecovirimate in human monkeypox cases. Monoclonal antibodies, IFN-β, resveratrol, and 15 triple-targeting FDA-approved drugs represent potential new drug targets for human monkeypox, necessitating further research.

show abstract

An overview of the progress made in research into the Mpox virus

Li,

Wang,

Chen

2024

Medicinal Research Reviews

View full text Add to dashboard Cite

Mpox is a zoonotic illness caused by the Mpox virus (MPXV), a member of the Orthopoxvirus family. Although a few cases have been reported outside Africa, it was originally regarded as an endemic disease limited to African countries. However, the Mpox outbreak of 2022 was remarkable in that the infection spread to more than 123 countries worldwide, causing thousands of infections and deaths. The ongoing Mpox outbreak has been declared as a public health emergency of international concern by the World Health Organization. For a better management and control of the epidemic, this review summarizes the research advances and important scientific findings on MPXV by reviewing the current literature on epidemiology, clinical characteristics, diagnostic methods, prevention and treatment measures, and animal models of MPXV. This review provides useful information to raise awareness about the transmission, symptoms, and protective measures of MPXV, serving as a theoretical guide for relevant institutions to control MPXV.

show abstract

Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database

Cited by 4 publications

References 28 publications

In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat

In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat

Monkeypox: From Emerging Trends to Therapeutic Concerns

An overview of the progress made in research into the Mpox virus

Contact Info

Product

Resources

About